Medical insurance coverage for Zanubrutinib

Zanubrutinib (Zanubrutinib)’s medical insurance reimbursement conditions include adult patients with mantle cell lymphoma (MCL) who have received at least one treatment in the past; adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one treatment in the past. The above indications are conditionally approved based on the objective response rate results of a single-arm clinical trial, and full approval will be dependent on the results of an ongoing confirmatory randomized controlled clinical trial; in adult patients with Waldenstrom's macroglobulinemia (WM) who have received at least one prior therapy, the above indications are conditionally approved based on the primary response rate results of a single-arm clinical trial.